(CNTX)
NCM – Real Time Price. Currency in USD
2.59
+0.05 (1.97%)
At close: Mar 27, 2026, 4:00 PM EDT
2.56
-0.03 (-1.16%)
After-hours: Mar 27, 2026, 4:47 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
2.59
+0.05 (1.97%)
At close: Mar 27, 2026, 4:00 PM EDT
2.56
-0.03 (-1.16%)
After-hours: Mar 27, 2026, 4:47 PM EDT
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Karen Chagin M.D. | Chief Medical Officer |
| Mr. Alex C. Levit Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Christopher Beck M.B.A. | Senior Vice President of Operations |
| Mr. Jeffrey Liebman | Associate Director of Accounting |
| Mr. Martin A. Lehr | Co-Founder, President, CEO & Director |
| Ms. Jennifer Dashnau M.B.A., Ph.D. | Senior Vice President of Technical Operations |
| Ms. Jennifer Minai-Azary | CFO & Treasurer |
| Date | Type | Document |
|---|---|---|
| 2026-03-13 | 8-K | cntx-20260311.htm |
| 2026-01-08 | 8-K | cntx-20260108.htm |
| 2025-11-05 | 8-K | cntx-20251105.htm |
| 2025-10-24 | 8-K | cntx-20251024.htm |
| 2025-10-20 | 8-K | cntx-20251017.htm |
| 2025-09-02 | 8-K | cntx-20250828.htm |
| 2025-08-06 | 10-Q | cntx-20250630.htm |
| 2025-06-12 | 8-K | cntx-20250612.htm |
| 2025-06-02 | 8-K | cntx-20250602.htm |
| 2025-05-07 | 10-Q | cntx-20250331.htm |